Sarah Noonberg
Chief Tech/Sci/R&D Officer bei METAGENOMI, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Sarah B.
Noonberg is currently serving as an Independent Director at Marinus Pharmaceuticals, Inc., Neurogene, Inc., and as the Chief Medical Officer at Metagenomi, Inc. She previously worked as the Director of Clinical Development at Chiron Corp.
from 2004 to 2007.
Sarah also held positions as a Director at Aquinox Pharmaceuticals, Inc., an Independent Director at Protagonist Therapeutics, Inc. from 2017 to 2023, a Director at Neoleukin Therapeutics, Inc., and an Independent Director at Neoleukin Therapeutics, Inc. from 2019 to 2023.
She served as the Group VP & Head of Global Clinical Development at BioMarin Pharmaceutical, Inc. from 2015 to 2017 and as the Senior Vice President of Early Development at Medivation, Inc. Sarah was also the Chief Medical Officer at Prothena Corp.
Plc from 2017 to 2018, at Nohla Therapeutics, Inc. from 2018 to 2019, and at Maze Therapeutics, Inc. from 2020 to 2022.
Additionally, she held the position of Chief Medical Officer at Metagenomi Technologies LLC.
Dr. Noonberg completed her undergraduate studies at Dartmouth College and obtained doctorate degrees from the University of California, Berkeley, and the University of California, San Francisco.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
METAGENOMI, INC.
0,27% | 01.04.2024 | 100 374 ( 0,27% ) | 1 Mio $ | 31.03.2024 |
| 01.04.2024 | 2 399 ( 0,00% ) | 21 687 $ | 31.03.2024 | |
| 15.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Sarah Noonberg
| Unternehmen | Position | Beginn |
|---|---|---|
| METAGENOMI, INC. | Chief Tech/Sci/R&D Officer | 01.01.2023 |
| MARINUS PHARMACEUTICALS, INC. | Director/Board Member | 16.05.2023 |
Ehemalige bekannte Positionen von Sarah Noonberg
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROGENE INC. | Director/Board Member | 01.12.2023 |
| PROTAGONIST THERAPEUTICS, INC. | Director/Board Member | 25.05.2023 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01.09.2022 |
Nohla Therapeutics, Inc.
 Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Chief Tech/Sci/R&D Officer | 01.05.2019 |
| PROTHENA CORPORATION PLC | Chief Tech/Sci/R&D Officer | 01.03.2018 |
Ausbildung von Sarah Noonberg
| Dartmouth College | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| PROTHENA CORPORATION PLC | Health Technology |
| METAGENOMI, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
| Medivation, Inc. /Old/ | Health Technology |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Nohla Therapeutics, Inc.
Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical firm utilizing sophisticated computational methods. develop and designs de novo protein therapeutics. The company was is headquartered in Seattle, WA. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Metagenomi Technologies LLC
 Metagenomi Technologies LLC BiotechnologyHealth Technology Metagenomi Technologies LLC engages in the development of curative therapeutics and gene-editing technologies and therapies. The company was founded by Brian C. Thomas in September 2016 and is headquartered in Emeryville, CA. | Health Technology |
